# Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

> **NCT03109093** · PHASE2 · COMPLETED · sponsor: **Goethe University** · enrollment: 83 (actual)

## Conditions studied

- ALL, Recurrent, Adult

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03109093
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2021-08-15
- **Final completion:** 2023-03-10
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109093, "Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03109093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*